The absence of TMM in human somatic cells makes TMM-specific vulnerabilities attractive targets for personalized cancer therapy22; however, it is critical to efficiently distinguish between ALT+ and TERT+ cancers, which is currently challenging in the clinical setting. This evidence concerns the gene TERT and cancer.